In severe, uncontrolled asthma, tezepelumab reduced exacerbations over 1 y regardless of type 2 inflammation level

被引：1
作者：
Estrada, Rodolfo A. [1 ]
Maselli, Diego J. [1 ]
机构：
[1] UT Hlth San Antonio, San Antonio, TX 78229 USA
来源：
ANNALS OF INTERNAL MEDICINE | 2023年 / 176卷 / 11期
关键词：
ADULTS;
D O I：
10.7326/J23-0084
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Source Citation Corren J, Menzies-Gow A, Chupp G, et al. Efficacy of tezepelumab in severe, uncontrolled asthma: pooled analysis of the PATHWAY and NAVIGATOR clinical trials. Am J Respir Crit Care Med. 2023;208:13-24. 37015033 Clinical Impact Ratings GIM/FP/GP: Pulmonology:
引用
收藏
页码：JC128 / JC128
页数：1
相关论文
共 7 条
  • [1] Type 2 Low Biomarker Stability and Exacerbations in Severe Uncontrolled Asthma
    Viinanen, Arja
    Aakko, Juhani
    Lassenius, Mariann I.
    Telg, Gunilla
    Nieminen, Kaisa
    Kaijala, Saara
    Lehtimaki, Lauri
    Kankaanranta, Hannu
    BIOMOLECULES, 2023, 13 (07)
  • [2] The Clinical Efficacy of Type 2 Inflammation-Specific Agents Targeting Interleukins in Reducing Exacerbations in Severe Asthma: A Meta-Analysis
    Lee, Jonghoo
    Song, Jae-Uk
    Kim, Yee Hyung
    YONSEI MEDICAL JOURNAL, 2022, 63 (06) : 511 - 519
  • [3] Next-Generation Therapeutic Approaches for Uncontrolled Asthma: Insights Into the Heterogeneity of Non-Type 2 Inflammation
    Kim, So Ri
    ALLERGY ASTHMA & IMMUNOLOGY RESEARCH, 2024, 16 (01) : 1 - 5
  • [4] Effect of tezepelumab on airway inflammatory cells, remodelling, and hyperresponsiveness in patients with moderate-to-severe uncontrolled asthma (CASCADE): a double-blind, randomised, placebo-controlled, phase 2 trial
    Diver, Sarah
    Khalfaoui, Latifa
    Emson, Claire
    Wenzel, Sally E.
    Menzies-Gow, Andrew
    Wechsler, Michael E.
    Johnston, James
    Molfino, Nestor
    Parnes, Jane R.
    Megally, Ayman
    Colice, Gene
    Brightling, Christopher E.
    LANCET RESPIRATORY MEDICINE, 2021, 9 (11) : 1299 - 1312
  • [5] Expression of eosinophil β chain-signaling cytokines receptors, outer-membrane integrins, and type 2 inflammation biomarkers in severe non-allergic eosinophilic asthma
    Kalinauskaite-Zukauske, Virginija
    Januskevicius, Andrius
    Janulaityte, Ieva
    Miliauskas, Skaidrius
    Malakauskas, Kestutis
    BMC PULMONARY MEDICINE, 2019, 19 (01)
  • [6] Effect of tralokinumab, an interleukin-13 neutralising monoclonal antibody, on eosinophilic airway inflammation in uncontrolled moderate-to-severe asthma (MESOS): a multicentre, double-blind, randomised, placebo-controlled phase 2 trial
    Russell, Richard J.
    Chachi, Latifa
    FitzGerald, J. Mark
    Backer, Vibeke
    Olivenstein, Ronald
    Titlestad, Ingrid L.
    Ulrik, Charlotte Suppli
    Harrison, Timothy
    Singh, Dave
    Chaudhuri, Rekha
    Leaker, Brian
    McGarvey, Lorcan
    Siddiqui, Salman
    Wang, Millie
    Braddock, Martin
    Nordenmark, Lars H.
    Cohen, David
    Parikh, Himanshu
    Colice, Gene
    Brightling, Christopher E.
    LANCET RESPIRATORY MEDICINE, 2018, 6 (07) : 499 - 510
  • [7] High mobility group box 1: a novel mediator of Th2-type response-induced airway inflammation of acute allergic asthma
    Ma, Libing
    Zeng, Jinrong
    Mo, Biwen
    Wang, Changming
    Huang, Jianwei
    Sun, Yabing
    Yu, Yuanyuan
    Liu, Shaokun
    JOURNAL OF THORACIC DISEASE, 2015, 7 (10) : 1732 - 1741
1